Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 7,046 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: High dose Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Food Effects on Milademetan Pharmacokinetics in Healthy Participants

NCT03647202
View directory record Official record
Conditions
Food Effects on Pharmacokinetics
Interventions
Milademetan Treatment A, Milademetan Treatment B, Milademetan Treatment C
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

High and Low Dose Carbidopa Treatment of Parkinson's Disease

NCT01399905
View directory record Official record
Conditions
Parkinson's Disease
Interventions
carbidopa
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
35 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation

NCT00003966
View directory record Official record
Conditions
Veno-occlusive Disease
Interventions
defibrotide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 18 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
9
States / cities
Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 17, 2026, 5:41 PM EDT
Terminated Phase 2 Interventional Results available

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

NCT02370095
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Treprostinil Inhalation Solution, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)

NCT00157716
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury, Myocardial Revascularization
Interventions
(MC-1) Pyridoxal-5'-phosphate
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2006 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects

NCT06802185
View directory record Official record
Conditions
Pain
Interventions
ADA Liquid Filled Capsules (Test Product), ADA Caplets (Reference Product), Advil Liqui-gels (Reference Product)
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Safety and Efficacy Evaluation of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation

NCT02822508
View directory record Official record
Conditions
Constipation
Interventions
BLI801 Laxative, BLI801 Placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years to 84 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
73
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 17, 2026, 5:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450
View directory record Official record
Conditions
Advanced Solid Tumors Cancer, MSI-H Cancer
Interventions
NDI-219216
Drug
Lead sponsor
Nimbus Wadjet, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
Los Angeles, California • Chicago, Illinois • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

A Controlled Laboratory Study of the Effects on Cue-Induced Craving in Dependent Smokers

NCT00901459
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Active rTMS Condition, rTMS Location Control Condition, rTMS Frequency Control Condition
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Vitamin D Supplementation in HIV Youth

NCT01523496
View directory record Official record
Conditions
HIV Infections
Interventions
Vitamin D control dose, Vitamin D supplementation-
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
8 Years to 25 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

NCT03255096
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma
Interventions
RO6870810, Venetoclax, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Duarte, California • Stanford, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Phase 3 Interventional

Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation

NCT01006876
View directory record Official record
Conditions
Thromboembolism
Interventions
Coumadin
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

NCT01577550
View directory record Official record
Conditions
Psoriasis
Interventions
BI 655066 (very high i.v. dose), Placebo, i.v., BI 655066 (high s.c. dose), BI 655066 (low i.v. dose), BI 655066 (high medium i.v. dose), BI 655066 (very low i.v. dose), BI 655066 (low s.c. dose), BI 655066 (high i.v. dose), Placebo, s.c., BI 655066 (low medium i.v. dose)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Burbank, California • Miami, Florida • Port Orange, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Oct 17, 2026, 5:41 PM EDT
Withdrawn Not applicable Interventional

Acupuncture for Mucositis Pain in Cancer Care

NCT00549835
View directory record Official record
Conditions
Mucositis, Pain, Leukemia
Interventions
Real Acupuncture, Sham Acupuncture
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Results available

FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care

NCT03694808
View directory record Official record
Conditions
Flu
Interventions
Fluad Vaccine, Fluzone HD Vaccine
Drug
Lead sponsor
David H. Canaday
Other
Eligibility
65 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

NCT04707768
View directory record Official record
Conditions
Anemia Associated With Chronic Kidney Disease (CKD)
Interventions
Vadadustat, Mircera®
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
58
States / cities
Huntsville, Alabama • Phoenix, Arizona • Pine Bluff, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

NCT00159874
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
11
States / cities
Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 17, 2026, 5:41 PM EDT
Recruiting Phase 3 Interventional

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 5:41 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Mechanistic Evaluation of Polypharmacy Effects for Pain

NCT07846020
View directory record Official record
Conditions
Chronic Lower Back Pain (CLBP)
Interventions
Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 17, 2026, 5:41 PM EDT
Recruiting Phase 1 Interventional

Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

NCT07211659
View directory record Official record
Conditions
Ovarian Cancer
Interventions
THEO-260
Biological
Lead sponsor
Theolytics Limited
Industry
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 17, 2026, 5:41 PM EDT
Terminated Phase 2 Interventional Results available

T-Cell Depleted Double UCB for Refractory AML

NCT01464359
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Refractory Acute Myelogenous Leukemia
Interventions
Allopurinol, Fludarabine, Total body irradiation, Cyclophosphamide, Levetiracetam, Busulfan, Umbilical Cord Blood Transplantation, Interleukin-2
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Not applicable Interventional

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

NCT01097278
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions
cholecalciferol, placebo
Dietary Supplement · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 50 Years · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
360
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 230 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 17, 2026, 5:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutrition Intervention During Chemotherapy

NCT01871350
View directory record Official record
Conditions
Cancer Patients Receiving Chemotherapy or Chemoradiotherapy
Interventions
Daily intake for 10 weeks (+/- 2 weeks)
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 17, 2026, 5:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

NCT03850535
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 17, 2026, 5:41 PM EDT